tbuckley/cabot-search huggingface dataset:
PS1572 HEART DISEASE AND PANCREATIC IRON IN THALASSEMIA MAJOR
Authors: A. Meloni, L. Pistoia, V. Spadola, M. Murgia, A. Quota, V. Carrai, S. Bulgarelli, R. Mattei, M. Pasin, L. Sardella, G. Restaino, P. Preziosi, V. Positano, A. Pepe
Journal: HemaSphere (2019)

Background: Some preliminary data have postulated a correlation between pancreatic iron overload and heart iron and function in thalassemia major (TM) patients. Aims: In the present multicenter study we explored systematically the link between pancreatic iron and heart disease in a large cohort of TM patients. Methods: We considered 880 TM patients (467 M, mean age 37.83 ± 10.05 years) enrolled in the E‐MIOT (Extension‐Myocardial Iron Overload in Thalassemia) project. T2 ∗ measurements were performed over pancreatic head, body and tail and global value was the mean. Myocardial iron overload (MIO) was quantified using a T2 ∗ segmental approach. Biventricular function parameters were assessed by cine images. Late gadolinium enhancement (LGE) images were acquired to detect myocardial fibrosis. Results: A significant correlation between pancreatic and cardiac iron was reconfirmed in this more numerous population and a normal pancreas T2 ∗ showed negative predictive value of 100% for cardiac iron. LGE sequences were acquired in 273 TM patients and 84 (30.77%) of them showed macroscopic myocardial fibrosis. Global pancreas T2 ∗ values were significantly lower in patients with fibrosis (7.38 ± 6.19 ms vs 11.91 ± 9.79 ms; P &lt; 0.0001). Sixty‐four patients had at least one cardiac complication (arrhythmias, heart failure, pulmonary hyperthension, vascular disease). Patients with cardiac complications showed a significant lower global pancreas T2 ∗ (7.83 ± 5.61 ms vs 12.76 ± 10.34 ms; P = 0.024). Specifically, global pancreas T2 ∗ values were significantly lower in patients with heart failure as well as in patients with arrhythmias and all patients with one of these two diseases had a pathologic global pancreas T2 ∗ value (see Figure). Summary/Conclusion: Pancreatic iron is a strong predictor not only for cardiac iron, but also for cardiac complications supporting a more profound link between pancreatic iron and heart disease in TM. image
AB1169 ASSOCIATION OF ANXIETY, DEPRESSION WITH ULTRASONOGRAPHIC EVALUATION OF THE JOINTS, DISEASE ACTIVITY, FUNCTIONAL DISABILITY AND QUALITY OF LIFE IN PATIENTS WITH RHEUMATIC DISEASES:
Authors: Rita Osipyants, Victoria Nadtocheeva, Madina Bogdanova, Marina Kanevskaya, Temuri Mirilashvili
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Objectives</h3> The aim of this study is to evaluate anxiety and depression disorders and to study their correlation with disease activity, ultrasonographic (US) finding indicative of synovitis, functional status and quality of life in patients (pts) with rheumatic diseases. <h3>Methods</h3> 39 pts (F/M–29/10) with rheumatoid arthritis (RA, n=17), ankylosing spondylitis (AS, n=10), psoriatic arthritis (PsA, n=12) were included. All RA pts fulfilled the ACR/EULAR 2010, AS pts - the ASAS, PsA pts - the CASPAR criteria. 20 pts (8 RA, 6 AS, 6 PsA) were performed US examinations (Mindray DC-N6 (China), C5-2, L10-13 MHz probes) included bilateral of the hip and knee joints. Each joint was scored according to the OMERACT definitions of pathology. Functional status (BASFI), disease activity indices (DAS28-CRP, ASDAS-CRP, DAPSA), anxiety and depression levels (Hads-A, Hads-D) and quality of life (RAPID3, EQ-5D) were assessed. The Mann-Whitney U-test was applied for intergroup comparison and correlation was evaluated using a Spearman's Rank two-tailed test (<i>R</i> value is shown). <h3>Results</h3> Median age of 39 pts - 52 (44;61) years and the body mass index – 28 (23;30). Mean anxiety index was 6.7±3.4, depression index - 6.6±3.3. Anxiety disorders were detected in 13/39 pts (33.3%), depression disorders in 17/39 pts (43.5%). Pts with Hads-D ≥8 (n=17) had higher score ASDAS-CRP (4.6 (4.2;5.0) vs 3.1 (2.7;3.9), p&lt;0.01), BASFI (7.2 (6;7.3) vs 4.2 (3;5.5), p&lt;0.05), EQ-5D index (9.8 ±1.2 vs 8.5±1.6, p&lt;0.01) and the same tendency to US score and DAS28-CRP compared pts without depression. But pts with Hads-A ≥8 (n=13) had only higher EQ-5D (10 ±1.2 vs 8.7±1.6, p&lt;0.005) and RAPID3 (17.1 ±5.8 vs 15.6±1.6, p&lt;0.05). However, US – synovitis of the hip joints was positively correlated with Hads-D (r=0.713, p&lt;0.05) and Hads-A (r=0.587, p&lt;0.05). <h3>Conclusion</h3> Anxiety and depression more common in patients with active rheumatic diseases. Psychological disorders are associated with disease activity, US- finding of synovitis and the severity of functional disability. <h3>Disclosure of Interests</h3> None declared
PB2270 THE RELATIONSHIP BETWEEN OXIDATIVE STRESS MARKERS, AGE, NEUTROPHIL‐TO‐LYMPHOCYTE RATION AND OBESITY
Authors: M.‐A. Gaman, M. E. Epingeac, A. M. Gaman
Journal: HemaSphere (2019)

Background: Obesity is a complex metabolic disease associated with an excessive accumulation of white adipose tissue (WAT). WAT secretes adipokines, which in turn generate reactive oxygen species (ROS) or decrease the total antioxidant capacity (TAC), and pro‐inflammatory cytokines (TNF‐alpha, IL1, IL6), leading to obesity‐induced inflammation. Aims: To evaluate oxidative stress via ROS and TAC measurement and evaluate obesity‐induced inflammation via the neutrophil‐to‐lymphocyte ratio (NLR) in obese patients. Methods: We evaluated oxidative stress and NLR in obese subjects vs. non‐obese controls. Patients were divided by age, sex, and degree of obesity. Obesity was diagnosed according to the WHO criteria, based on the body mass index (BMI). Oxidative stress was evaluated using a CR3000 analyzer via the FORT (Free Oxygen Radical Testing for ROS quantification) and FORD (Free Oxygen Radical Defence for TAC measurement) assays. NLR was evaluated as a marker of chronic inflammation (normal values: 0.78‐3.53). Statistical analysis of data was conducted using the student T‐test and a p‐value &lt; 0.05 was considered significant. The study was approved by the Ethics Committee of the University of Medicine and Pharmacy of Craiova (approval no. 40/27.03.2018) and written informed consent was collected from all subjects involved. Results: The study group involved 85 obese patients (mean age 61.85 ± 10.60 years, age range 24‐82): 17 males (20.00%, mean age 62.65 ± 8.90 years, age range 43‐77) and 68 females (80.00%, mean age 61.65 ± 10.97 years, age range 24‐82). The control group included 30 non‐obese subjects (mean age 44.60 ± 18.45 years, age range 18‐85). Mean BMI was 36.44 ± 3.63 kg/m 2 in obese subjects (men: 35.35 ± 3.41 kg/m 2 , women: 36.71 ± 3.63 kg/m 2 ) vs. 24.56 ± 1.76 kg/m 2 in controls (p‐value &lt; 0.0001). Stratification in obesity classes was: 38 patients (44.70%) ‐ class I obesity, 31 patients (36.47%) ‐ class II obesity, 16 patients (18.83%) – class III obesity. FORT values were increased in obese patients vs. controls (3.09 ± 0.36 mmol/L vs. 2.03 ± 0.14 mmol/L, p‐value&lt;0.001). FORD values were decreased in obese patients vs. controls (0.69 ± 0.15 mmol/L vs. 1.27 ± 0.13 mmol/L, p‐value&lt;0.001). We did not record significant differences in terms of NLR in obese subjects vs. controls (2.46 ± 0.96 vs. 2.31 ± 0.26, p = 0.4036). In obese subjects, we found positive correlations between FORT and BMI ( r s = 0.38407, p = 0.00028), NLR ( r s = 0.06771, p = 0.5381) and age ( r s = 0.06781, p = 0.53748). Negative correlations were recorded between FORD and BMI (r s = ‐0.35083, p = 0.001), age (r s = ‐0.04698, p = 0.66942) and NLR (r s = ‐0.06732, p = 0.54045) Summary/Conclusion: In our study group, ROS levels were increased and TAC was decreased in obese patients as compared to healthy controls. ROS levels and TAC correlated with BMI, but not in a significant manner with age or NLR.
Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial
Authors: Grace L H Wong, Louis H S Lau, Jessica Y L Ching, Yee-Kit Tse, Rachel H Y Ling, Vincent W S Wong, Philip W Y Chiu, James Y W Lau, Francis K L Chan
Journal: Gut (2019)

Objective Patients with a history of Helicobacter pylori -negative idiopathic bleeding ulcers have a considerable risk of recurrent ulcer complications. We hypothesised that a proton pump inhibitor (lansoprazole) is superior to a histamine 2 receptor antagonist (famotidine) for the prevention of recurrent ulcer bleeding in such patients. Design In this industry-independent, double-blind, randomised trial, we recruited patients with a history of idiopathic bleeding ulcers. After ulcer healing, we randomly assigned (1:1) patients to receive oral lansoprazole 30 mg or famotidine 40 mg daily for 24 months. The primary endpoint was recurrent upper GI bleeding within 24 months, analysed in the intention-to-treat population as determined by an independent adjudication committee. Results Between 2010 and 2018, we enrolled 228 patients (114 patients in each study group). Recurrent upper GI bleeding occurred in one patient receiving lansoprazole (duodenal ulcer) and three receiving famotidine (two gastric ulcers and one duodenal ulcer). The cumulative incidence of recurrent upper GI bleeding in 24 months was 0.88% (95% CI 0.08% to 4.37%) in the lansoprazole arm and 2.63% (95% CI 0.71% to 6.91%) in the famotidine arm (p = 0.313; crude HR 0.33, 95% CI 0.03 to 3.16, p = 0.336). None of the patients who rebled used aspirin, non-steroidal anti-inflammatory drugs or other antithrombotic drugs. Conclusion This 2-year, double-blind randomised trial showed that among patients with a history of H. pylori -negative idiopathic ulcer bleeding, recurrent bleeding rates were comparable between users of lansoprazole and famotidine, although a small difference in efficacy cannot be excluded. Trial registration number NCT01180179 ; Results.
SP0162 REMISSION IN RA: DOES THE DEFINITION MATTER?
Authors: Daniel Aletaha
Journal: Annals of the Rheumatic Diseases (2019)

<h3></h3> Remission is the ultimate target for chronic inflammatory rheumatic disease, and so also for rheumatoid arthritis (RA). In this presentation, we will review the challenges in defining and assessing remission. Further, we will discuss if remission should be a clinical target, or whether imaging results, e.g. from ultrasound or MRI examinations, should be included in the concept of remission. Many symptoms in patients with RA may mimick RA disease activity, while they are not directly a consequence of the disease process, with secondary pain syndromes being a typical example. FInally, patients are the most important stakeholders on the question of whether or not a musculoskeletal disease is in remission. Patient reported outcomes have been critizised for their subjectivity and their role in remission indices has been questioned. We will also explore the influence and Pro"s and Con"s of these measures on remission assessment. <h3>Disclosure of Interests:</h3> Daniel Aletaha Grant/research support from: AbbVie, Bristol-Myers Squibb, and MSD, Consultant for: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Medac, Merck, MSD, Pfizer Inc, Roche, and UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Medac, Merck, MSD, Pfizer Inc, Roche, and UCB
SP0098 CRYSTAL ARTHROPATHIES: IS THERE A ROLE FOR MRI?
Authors: Kay-Geert Hermann
Journal: Annals of the Rheumatic Diseases (2019)

<h3></h3> The plain radiographic features of gout are well known. However, the sensitivity of plain radiographs alone for the detection of signs of gout is poor in acute disease. Dual-energy computed tomography (DECT) and ultrasonography fill the gap for early and specific detection. However, there are instances in which MRI of the painful joints was already acquired. Therefore, it is crucial to know the imaging findings of gout in MRI. MRI per se is not suitable for imaging the calcified bone or soft tissue calcifications. However, there are special techniques such as gradient echo sequences or susceptibility-weighted imaging (SWI) to visualize calcifications. Furthermore, the inflamed joint with all its characteristics such as synovitis, tenosynovitis, and erosions is easily accessible by MRI. Specific findings in the differentiation of RA, PsA, and gout are presented. The presentation will be case-based, and participants will have the opportunity to test their knowledge. <h3>Disclosure of Interests:</h3> Kay-Geert Hermann Paid instructor for: MSD, AbbVie, Novartis, but less than 10.000€
SP0191 MANAGEMENT OF ADULT APS: RECOMMENDATIONS FROM AN EULAR TASK FORCE
Authors: Maria Tektonidou
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by arterial and venous thrombotic events or pregnancy morbidity in the presence of persistently positive antiphospholipid antibodies. There is a great heterogeneity in clinical and laboratory classification of the syndrome and treatement approaches over the past four decades. <h3>Objectives:</h3> To develop evidence-based recommendations for the prevention and management of adult APS that will help guide clinical practice. <h3>Methods:</h3> EULAR standardised operating procedures were followed. A task force was formed including 21 physicians, 1 healthcare professional, and 2 patients, from 11 countries. Research questions were developed using the Delphi method. A systematic literature review of published articles up to January 2018 was performed. <h3>Results:</h3> Based on the evidence and experts opinion, a set of 3 overarching principles and 12 recommendations including their level of evidence and grade of recommendation was developed and voted. The level of agreement for each recommendation was high. The overarching principles include the risk stratification, general measures, and education/counselling of patients with APS. Recommendations for primary prevention address the primary thromboprophylaxis (low dose aspirin vs no treatment) in antiphospholipid antibody individuals including asymptomatic carriers, patients with systemic lupus erythematosus without history of thrombotic or obstetric APS, and non-pregnant women with a history of obstetric APS only. Recommendations for the management of thrombotic manifestations address different types of anticoagulation in patients with definite APS and first provoked or unprovoked venous thrombosis and the management of recurrent venous thrombosis, as well as the type and intensity of anticoagulation in patients with first or recurrent arterial thrombosis. Recommendations for the management of obstetric APS describe the management of various types of pregnancy complications in APS and of refractory to treatment cases. Recommendations for catastrophic APS refer to precipitating factors, first-line treatment of catastrophic APS, and management of refractory cases. <h3>Conclusion:</h3> These recommendations based on evidence and expert opinion aim to guide practice and improve quality of care in patients with APS. <h3>Reference:</h3> [1] Tektonidou MG, Andreoli L, Limper M, et al. EULAR Recommendations for the management of Antiphospholipid Syndrome in adults. Ann Rheum Dis. 2019 <h3>Disclosure of Interests:</h3> None declared
A Contemporary Look at Biomechanical Models of Myocardium
Authors: Reza Avazmohammadi, João S. Soares, David S. Li, Samarth S. Raut, Robert C. Gorman, Michael S. Sacks
Journal: Annual Review of Biomedical Engineering (2019)

Understanding and predicting the mechanical behavior of myocardium under healthy and pathophysiological conditions are vital to developing novel cardiac therapies and promoting personalized interventions. Within the past 30 years, various constitutive models have been proposed for the passive mechanical behavior of myocardium. These models cover a broad range of mathematical forms, microstructural observations, and specific test conditions to which they are fitted. We present a critical review of these models, covering both phenomenological and structural approaches, and their relations to the underlying structure and function of myocardium. We further explore the experimental and numerical techniques used to identify the model parameters. Next, we provide a brief overview of continuum-level electromechanical models of myocardium, with a focus on the methods used to integrate the active and passive components of myocardial behavior. We conclude by pointing to future directions in the areas of optimal form as well as new approaches for constitutive modeling of myocardium.
THU0467 DOES GENERALISED PAIN AND LOCALISED PAIN SEVERITY INCREASE RISK OF PREVALENT AND INCIDENT FRACTURES IN OLDER ADULTS?
Authors: Feng Pan, Jing Tian, Dawn Aitken, Flavia Cicuttini, Graeme Jones
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Musculoskeletal pain is common particularly in the elderly and typically occurs in multiple sites. Pain has been linked to falls risk; however, whether increased risk of falls related to pain can subsequently increase fracture risks remains unclear. <h3>Objectives:</h3> To describe the associations of localised pain severity and generalised pain (number of painful sites) with incident fractures, and to explore whether their associations are independent of falls risk, bone mineral density (BMD) and potential confounders. <h3>Methods:</h3> Data from a longitudinal population-based study of older adults (mean age 63 years, 51% female) were utilised. A mean follow-up was performed at 2.6, 5.1 and 10.7 years later, respectively. Pain severity in the knee was measured by the Western Ontario and McMaster Universities Osteoarthritis Index pain questionnaire. Presence/absence of pain at the neck, back, hands, shoulders, hips, knees and feet was assessed by questionnaire at baseline. Fractures were self-reported at each time-point. BMD was measured by Dual-energy X-ray absorptiometry (DXA). Falls risk was calculated based on the short form Physiological Profile Assessment. <h3>Results:</h3> A total of 455 fractures at baseline and 154 new fractures were reported during follow-up. In multivariable analyses, both pain severity and number of painful sites were associated with prevalent fractures at any site. Pain severity was associated with prevalent vertebral fractures, while number of painful sites was associated with prevalent fractures at non-vertebral and hip sites. Furthermore, pain severity was associated with an increased risk of incident fractures at any site [relative risk (RR) 1.04, 95%CI 1.02-1.06], major (including the femur, radius, ulnar, vertebral, rib and humerus) (RR 1.10, 95%CI 1.05-1.15) and vertebral (RR 1.04, 95%CI 1.01-1.08). Similarly, number of painful sites was also associated with increased risk of incident fractures at any site [RR 1.69, 95%CI 1.13-2.53], major (RR 2.17, 95%CI 1.12-4.22) and vertebral (RR 6.44, 95%CI 1.64-25.33). There was a dose-response relationship between number of painful sites and risk of incident fractures. These associations remained significant after further adjustment for falls risk and BMD. No significant associations were found for fractures occurring at non-vertebral and hip sites. <h3>Conclusion:</h3> Both pain severity and generalised pain are associated with increased risk of prevalent and incident fractures, which is independent of falls risk, BMD and potential confounders, suggesting that pain may be an independent marker of fracture risk. Improved pain management may have the potential to prevent fractures in older adults. <h3><b>Disclosure of Interests:</b>&nbsp;:</h3> None declared
PB1916 MIRNAS AND ANGIOGENIC FACTORS IN PLASMA BEFORE AND AFTER TKI TREATMENT IN CML PATIENTS
Authors: Z. Litwińska, K. Łuczkowska, A. Sobuś, D. Rogińska, E. Pius‐Sadowska, E. Paczkowska, M. Gniot, K. Lewandowski, G. Helbig, B. Machaliński
Journal: HemaSphere (2019)

Background: The differences of an angiogenic potential between clinical phases of chronic myeloid leukemia (CML), point at the significance of neovascularisation in CML pathogenesis. Tyrosine kinase inhibitors (TKI), possessing antiangiogenic properties and microRNAs (miRNAs), implicated in governing angiogenesis, both seem vital in this process. Aims: In this study, we aimed to investigate how TKI treatment affects angiogenesis‐related miRNAs expression and angiogenic factors concentration in plasma of CML patients. Methods: Peripheral blood plasma samples were obtained from CML patients at the diagnosis (n = 23) and during TKI treatment (n = 12). Quantitative assessment of the expression of miRNA‐126‐3p, miRNA‐150‐5p and miRNA‐21‐3p was performed with qRT‐PCR. Concentrations of selected angiogenic factors in plasma (Angiogenin, bFGF, Endostatin,aFGF, PDGF‐AA, PIGF, Thrombospondin‐2, VEGF‐D, Angiopoietin‐1, VEGF) were assessed using multiplex fluorescent bead‐based immunoassays (Luminex Corporation). Results: MiRNA‐150‐5p and miRNA‐21‐3p expression was evidently higher in the treatment group (p = 0,001 and p = 0,03, respectively). PDGF‐AA concentration in newly diagnosed patients with CML was higher than in already treated patients (942,84 pg/ml vs 512,5 pg/ml, p = 0,02), similarly to VEGF (262,82 pg/ml vs 27 pg/ml, p = 0,03). Summary/Conclusion: TKI treatment affects miRNAs expression and angiogenic factors concentration in plasma of CML patients. MiRNAs could serve as biomarkers in monitoring CML progression and drug response, however, their exact role in CML‐related angiogenesis remains to be further elucidated.
Repeatability of Quantitative Brown Adipose Tissue Imaging Metrics on Positron Emission Tomography with 18F-Fluorodeoxyglucose in Humans
Authors: Tyler J. Fraum, John P. Crandall, Daniel R. Ludwig, Sihao Chen, Kathryn J. Fowler, Richard A. Laforest, Amber Salter, Farrokh Dehdashti, Hongyu An, Richard L. Wahl
Journal: Cell Metabolism (2019)
PB2263 THE SAFETY AND EFFICACY OF THE BIOSIMILAR ANTI-CD20 ANTIBODY, TRUXIMA, IN HEAMATOLOGICAL MALIGNANCY
Authors: I. Lo, S. Bansal, S. Arami
Journal: HemaSphere (2019)

Background: Truxima is the first biosimilar anti-CD 20 monoclonal antibody licensed by the European Commission for the treatment of cancer and launched in United Kingdom (UK) in April 2017. There are increasing centers introducing the Truxima in replacement to its originator (MabThera) in their clinical practice. However, there is currently limited real-life report on the efficacy and tolerability of Truxima and its cost saving benefit. Aims: This is a multi-centre study to evaluate the safety and overall response rate of Truxima in combination with chemotherapy in patient with an underlying haematological malignancy Methods: This is a local study conducted in London North West Hospital from 1st of October 2017 to 1st of April 2018 on patients who received Truxima with or without chemotherapy for B cell malignancy Results: There were 42 patients who received Truxima and 57% (24 out of 42) had a diagnosis of Diffuse Large B Cell Lymphoma (DLBCL). Truxima were generally well tolerated and 90% (38 out of 42) complication the infusion without any complications. There were three patients (7%) who experienced mild IRR which were all grade 2 or less. Amongst the patients who were diagnosed with Diffuse Large B Cell Lymphoma 33% (7 out of 21) achieved complete remission Summary/Conclusion: There were no specific concerns with Truxima as it has shown clinical similarity to MabThera in terms efficacy and safety. Truxima is 10% cheaper per 100 mg in comparison to Mabthera (£314.33 Vs £349.25), therefore it has the advantage of significant budget savings. In the current economic climate, these savings can have a significant impact on health gains at both patient and societal levels.